![](https://endpts.com/wp-content/uploads/2020/10/News_briefing_FE.jpg)
Compass Pathways' Phase IIb psilocybin trial shows reduced depression symptoms
UK biotech Compass Pathways revealed this morning that they reached the primary endpoint in a Phase IIb clinical trial of psilocybin …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.